ArticleFrontiers in nutrition2026
Hongjam, an edible silkworm-derived food, attenuates steatohepatitis and fibrosis via multi-axis modulation of metabolic stress, inflammation, and fibrogenic signaling.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease characterized by sustained inflammation and fibrosis, for which effective disease-modifying therapies remain limited. In this study, we investigated the hepatoprotective effects of Hongjam, a processed edible silkworm-derived food, in a methionine-choline-deficient (MCD) diet-induced mouse model of MASH. Methods: Histological analysis, plasma biochemical assessments, western blotting, quantitative PCR analyses, and in vitro experiments using macrophages and HepG2 hepatocyte-derived cells were performed to evaluate the effects of Hongjam and silk fibroin peptides associated with Hongjam. Results: Hongjam markedly alleviated hepatic injury, as evidenced by improved histological features, normalization of plasma biochemical parameters, and reduced collagen deposition. Mechanistically, Hongjam suppressed activation of the TGF-β/Smad signaling pathway, inhibited NF-κB-mediated inflammatory signaling, and attenuated MCD-associated metabolic stress signaling, including changes in AMPK phosphorylation and the expression of genes involved in fatty acid oxidation and lipid transport. Consistent with the in vivo findings, silk fibroin peptides associated with Hongjam attenuated NF-κB-mediated inflammatory signaling in macrophages and modulated TGF-β/Smad-associated signaling in HepG2 hepatocyte-derived cells in vitro. Discussion: Collectively, these results demonstrate that Hongjam attenuates experimental MASH by concurrently modulating metabolic stress, inflammation, and fibrotic remodeling. These findings highlight Hongjam as a food-derived candidate with potential relevance for dietary strategies targeting metabolic liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.